SHARPkids Omegas

High EPA, concentrated ultra-pure fish oil in liquid form to support cognitive and emotional development and overall health of children

• Highly concentrated, easy-to-take liquid
• Evidenced-backed high EPA (eicosapentaenoic acid) formula
• Supports childhood neuro and emotional development
• Promotes positive mood and behavior
• Superior triglyceride form
• 1/4 teaspoon supplies 350 mg EPA and 230 mg DHA
• Natural lemon flavor and no fishy taste or aftertaste

Patient One SHARPkids Omegas supplies highly purified and concentrated Omega-3 fatty acids as triglycerides in an easy-to-take liquid form. SHARPkids Omegas is formulated in a high EPA (eicosapentaenoic acid) to DHA (docosahexaenoic acid) ratio for targeted health benefits, and also includes a proprietary antioxidant blend.

Increasing evidence indicates that fatty acid deficiencies or imbalances contribute to childhood neurodevelopment disorders. Studies have linked levels of Omega-3 fatty acids in the blood to childrens ability to concentrate and learn as well as to behavior issues. Higher doses of EPA within essential fatty acids supplements was significantly associated with increased efficacy in treating symptoms related to cognition and behavior.

SHARPkids Omegas is a rich source of Omega-3 long-chain polyunsaturated fatty acids. With todays diets commonly lacking sufficient omega 3s, many children are deficient in EPA and DHA, the two most studied essential fatty acids in fish oil. These vital nutrients are important building blocks of child development and play key roles in every aspect of health, including brain and eye function. Omega-3s, particularly in higher EPA to DHA ratios, have been studied for their role in healthy neuro and emotional development, behavioral improvement, cardiovascular function, respiration and joint flexibility.

Certified pharmaceutical grade fish oil sourced from Norwegian cold water fish (anchovy, sardine, mackerel), SHARPkids Omegas is molecularly distilled and manufacturer-tested as well as third-party tested for contaminants and environmental pollutants including heavy metals, pesticides, dioxins and PCBs. Our processing technology and proprietary natural lemon flavoring ensures no fishy smell, taste, or aftertaste.

The "Triglyceride" Form Absorption Advantage
The many health benefits of Omega-3s can only be derived if your body absorbs the fatty acids. Although scientific research demonstrates the triglyceride form as the superior delivery mode of fish oil, very few fish oil concentrates in the marketplace are available in this form because of the higher production costs. Most fish oils contain the “ethyl ester" form of fatty acid, synthetic Omega-3 molecules, shown to be less effective in delivering essential fatty acids to the body during digestion and metabolism. SHARPkids Omegas supplies fish oil concentrate in the preferred re-esterified triglyceride form to optimize its effectiveness.

Research

• A pilot study evaluated the effects of high-dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on the isolated plasma phospholipids and behavior in nine children with ADHD (primarily inattentive subtype and combined subtype). At the end of the 8-week study, a psychiatrist (blind to supplement compliance or dosage modifications) reported significant improvements in behavior (inattention, hyperactivity, oppositional/defiant behavior, and conduct disorder). There was also a significant correlation between the reduction in the AA:EPA ratio and global severity of illness scores. The findings suggested supplementation with high-dose EPA/DHA concentrates may improve behavior in children with ADHD.
• Evidence supports that fatty acid deficiencies or imbalances in children or expectant mothers contributes to childhood neuro-developmental disorders.
• Research shows that subjects with lower compositions of total n 3 fatty acids had significantly more behavioral problems, temper tantrums, and learning, health, and sleep problems than did those with high proportions of n 3 fatty acids.

References

1. J Am Acad Child Adolesc Psychiatry. 2011 Oct; 50(10): 991–1000.
2. Bauer I, Hughes M, Rowsell R, Cockerell R, Pipingas A, Crewther S, and Crewther D. Omega-3 supplementation improves cognition and modifies brain activation in young adults. Hum. Psychopharmacol Clin Exp 2014: 29: 133-144.
3. Stevens L, Zentall S, Abate M, Kuczek T, Burgess J: Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol Behav 1996, 59:915-920.
4. Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR: Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2006, 75:299-308
5. Stevens L, Zentall S, Deck J, Abate M, Watkins B, Lipp S, Burgess J: Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995, 62:761-768.
6. Schuchardt JP, Huss M, Stauss-Grabo M, Hahn A. Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behavior of children. Eur J Pediatric 169: 149-164.
7. Richardson AJ, Montgomery P. The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics. 2005 May; 115(5): 1360-6.
8. Paul J Sorgi, et al. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutrition Journal 2007, 6:16
9. Ginty AT, Conklin SM. Short-term supplementation of acute long-chain omega-3 polyunsaturated fatty acids may alter depression status and decrease symptomology among young adults with depression: A preliminary randomized and placebo-controlled trial. Psychiatry Res. 2015 Sep 30;229(1-2):485-9.
10. Dyerberg J., et al. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids 2010 Sep;83(3): 137-141.
11. Bloch M., MD and Qawasmi A, MD. Omega-3 Fatty Acid Supplementation for the Treatment of Children with Attention-Deficit/Hyperactivity Disorder Symptomatology: Systematic Review and Meta-Analysis. J Am Acad Child Adolesc Psychiatry.2011 Oct.; 50(10):991-1000.